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Abstract
In recent years, a number of natural products isolated from Chinese herbs have been found to inhibit proliferation,
induce apoptosis, suppress angiogenesis, retard metastasis and enhance chemotherapy, exhibiting anti-cancer
potential both in vitro and in vivo. This article summarizes recent advances in in vitro and in vivo research on the
anti-cancer effects and related mechanisms of some promising natural products. These natural products are also
reviewed for their therapeutic potentials, including flavonoids (gambogic acid, curcumin, wogonin and silibinin),
alkaloids (berberine), terpenes (artemisinin, b-elemene, oridonin, triptolide, and ursolic acid), quinones (shikonin and
emodin) and saponins (ginsenoside Rg3), which are isolated from Chinese medicinal herbs. In particular, the
discovery of the new use of artemisinin derivatives as excellent anti-cancer drugs is also reviewed.
Background
Surgery, chemotherapy and radiotherapy are the main
conventional cancer treatment often supplemented by
other complementary and alternative therapies in China
[1]. While chemotherapy is one of the most extensively
studied methods in anti-cancer therapies, its efficacy
and safety remain a primary concern as toxicity and
other side effects of chemotherapy are severe. Moreover,
multi-drug resistant cancer is even a bigger challenge.
Medicinal herbs are main sources of new drugs. New-
man et al. reported that more than half of the new che-
micals approved between 1982 and 2002 were derived
directly or indirectly from natural products [2]. Some
active compounds have been isolated from Chinese
medicinal herbs and tested for anti-cancer effects. For
example, b-elemene, a compound isolated from Cur-
cuma wenyujin Y. H. Chen et C. Ling (Wenyujin), is
used as an anti-cancer drug in China. For this study, we
searched three databases, namely PubMed, Scopus and
Web of Science, using keywords “cancer”, “tumor”,
“neoplastic” and “Chinese herbs” or “Chinese medicine”.
Publications including research and review papers cov-
ered in this review were dated between 1987 and 2011,
the majority of which were published between 2007 and
2011. Chinese herb-derived ingredients, including flavo-
noids, alkaloids, terpenes, quinones and saponins, were
found.
Gambogic acid (GA)
GA (Figure 1A) is the principal active ingredient of
gamboges which is the resin from various Garcinia spe-
cies including Garcinia hanburyi Hook.f. (Tenghuang)
[3]. GA has various biological effects, such as anti-
inflammatory, analgesic and anti-pyretic [3] as well as
anti-cancer activities [4,5]. In vitro and in vivo studies
have demonstrated its potential as an excellent cytotoxi-
city against a variety of malignant tumors, including
glioblastoma, as well as cancers of the breast, lung and
liver. GA is currently investigated in clinical trials in
China [6-8].
GA induces apoptosis in various cancer cell types and
the action mechanisms of GA remain unclear. Transfer-
rin receptor (TfR) significantly over-expressed in a vari-
ety of cancers cells may be the primary target of GA [4].
The binding of GA to TfR in a manner independent of
the transferrin binding site, leading to the rapid apopto-
sis of tumor cells [4]. Proteomics analysis suggests that
stathmin may be another molecular target of GA [9].
The importance of the role of p53 in GA-induced apop-
tosis remains controversial [5,10]. Furthermore, GA
antagonizes the anti-apoptotic B-cell lymphoma 2
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2 proteins to various extents, most potently inhibiting
myeloid cell leukemia sequence 1 (Mcl-1) and Bcl-B, as
evidenced by a half maximal inhibitory concentration
(IC50) lower than 1 μM [11]. Moreover, GA also influ-
ences other anti-cancer targets, such as nuclear factor-
kappa B (NF-B) [12] and topoisomerase IIa [13].
GA causes a dose-dependent suppression of cell inva-
sion and inhibits lung metastases of MDA-MB-435 cells
in vivo through protein kinase C (PKC)-mediated matrix
metalloproteinase-2 (MMP-2) and matrix metallopepti-
dase-9 (MMP-9) inhibition [8]. GA also exhibits signifi-
cant anti-metastatic activities on B16-F10 melanoma
cancer cells partially through the inhibition of the cell
surface expression of integrin a4i nC57BL/6 mice [14].
Notably, the combination of GA with other com-
pounds enhances their anti-cancer activities [15-17]. For
example, He et al. [15] reports that proliferative inhibi-
tion and apoptosis induction are much more visibly
increased when Tca8113 cells are treated with combined
GA and celastrol, indicating that the combination of GA
and celastrol can be a promising modality for treating
oral squamous cell carcinoma. Another study showed
that GA in combined use with 5-fluorouracil (5-FU)
induced considerably higher apoptosis rates in BGC-823
human gastric cells and inhibited tumor growth in
human xenografts [16]. Furthermore, low concentrations
of GA were found to cause a dramatic increase in doce-
taxel-induced cytotoxicity in docetaxel-resistant BGC-
823/Doc cells [17]. Magnetic nanoparticles of Fe3O4
(MNPs-Fe3O4) were reported to enhance GA-induced
cytotoxicity and apoptosis in K562 human leukemia
cells [18].
Curcumin
Curcumin (Figure 1B) is the main active flavonoid
derived from the rhizome of Curcuma longa (Jian-
ghuang), with its dry herb weight consisting of up to
3.08% curcumin [19]. Curcumin has been used to treat
cardiovascular disease, inflammation and arthritis [20].
Figure 1 Chemical structures of the compounds. (A) gambogic acid; (B) curcumin; (C) wogonin; (D) silibinin; (E) berberine; (F) artemisinin; (G)
artesunate; (H) b-elemene; (I) oridonin; (J) triptolide; (K) ursolic acid; (L) shikonin; (M) emodin; (N) ginsenoside Rg3.
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several cancers is low in India where curcumin is widely
consumed, suggesting that curcumin intake plays a role
in cancer prevention [21]. Other studies have also indi-
cated that curcumin inhibits cell proliferation and survi-
val in breast cancer, colon cancer, prostate cancer,
gastric cancer, leukemia, lymphoma and melanoma [20].
Curcumin induces cell apoptosis through complex
intrinsic and extrinsic pathways. Curcumin binds to
more than 30 different protein targets, including tran-
script factors (NF-B and activator protein-1), growth
factor receptors [epidermal growth factor receptor
(EGFR), human epidermal growth factor receptor 2
(HER2)], kinases [mitogen-activated protein kinase
(MAPK), PKC and protein kinase A (PKA)], inflamma-
tory cytokines [tumor necrosis factor (TNF) and inter-
leukins], cell cycle-related proteins (p53 and p21),
matrix metalloproteinases (MMPs) and urokinase plas-
minogen activators (u-PA) [20,22,23]. Daily oral admin-
istration of curcumin suppresses metastasis in breast,
colon, lung and medulloblastoma cancers. The suppres-
sion involves the regulation of metastatic proteins, such
as vascular endothelial growth factor (VEGF), MMP-2,
MMP-9 and intercellular adhesion molecules [24,25].
Curcumin induces non-apoptotic cell death, such as
autophagic cell death, which involves the degradation of
the cell’s own components through lysosomal machinery
[23]. In vitro and in vivo studies have demonstrated that
curcumin induces autophagic cell death, as evidenced by
the immunoreactivity of microtubule-associated protein
light chain 3 (LC3) in myeloid leukemia cells. The
action mechanism is attributed to the inhibition of the
Akt/mammalian target of rapamycin/p70 ribosomal pro-
tein S6 kinase pathway and activation of extracellular
signal-regulated kinase 1/2b yc u r c u m i ni nm a l i g n a n t
glioma cells [26,27]. In addition, autophagic inhibitor
bafilomycin A1 suppresses curcumin-induced cell death
[28]. Another type of non-apoptotic cell death induced
by curcumin is paraptosis which is observed in malig-
nant breast cancer cells but not in normal breast cells.
Curcumin induces paraptotic events (eg the promotion
of vacuolation accompanied with mitochondrial and/or
endoplasmic reticular swelling and fusion) and decreases
the level of paraptotic inhibitor protein AIP-1/Alix [29].
These paraptotic events are attributed to superoxide
anion and proteasomal dysfunction [29].
Curcumin reduces toxicity induced by anti-cancer
agents [30], sensitizes chemo-resistant cancer cells and
demonstrates synergic effects with different chemothera-
peutic agents such as doxorubicin, 5-FU, paclitaxel, vin-
cristine, melphalan, butyrate, cisplatin, celecoxib,
vinorelbine, gemcitabine, oxaliplatin, etoposide, sulfino-
sine, thalidomide, suberoylanilide hydroxamic acid, dasa-
tinib and bortezomib [30]. Prior administration of
curcumin reduces the DNA damage and oxidative stress
induced by cyclophosphamide (CXC) [31], improves
uroprotective efficacy in the CXC hemorrhagic cystitis
model [32] and suppresses early lung damage in CXC-
treated rats [33]. Curcumin alleviates the side effects of
mitomycin C, as evidenced by decreased lipid peroxida-
tion and DNA damage [34]. Furthermore, curcumin
reduces weight loss and improves kidney function and
bone marrow suppression in animal studies [35]. When
combined with oxaliplatin, curcumin decreases the pro-
liferative capacity of oxaliplatin-resistant cell lines and
enhances the cytotoxicity of oxaliplatin in an in vitro
oxaliplatin-resistant model [36]. Additionally, curcumin
protects healthy cells against radiation and sensitizes
tumor cells to radiation therapy [37,38].
Clinical trials have been or are currently being con-
ducted to evaluate the tolerance, safety, pharmacoki-
netics and efficiency of curcumin as well as its
combination therapy with current anti-cancer drugs
[39]. A phase I clinical trial found no dose-limiting toxi-
city in patients treated with an oral-dose of up to 8g/
day of curcumin. The recommendation is seven conse-
cutive doses (6g/day) of curcumin every three weeks in
combination with a standard dose of docetaxel [40].
Improvements in biological and clinical responses were
observed in most treated patients [40]. A phase II trial
of gemcitabine-resistant pancreatic cancer found che-
motherapeutic drugs in combined use with curcumin to
be sufficiently safe, feasible and efficient. While the bioa-
vailability of curcumin is relatively poor, two out of 21
patients in the phase II trial showed clinical biological
responses; one patient exhib i t e dm a r k e dt u m o rr e g r e s -
sion coupled with a significant increase in serum cyto-
kine levels [41,42].
Wogonin
Wogonin (Figure 1C) is one of the flavonoids isolated
from Scutellaria baicalensis Georgi (Huangqin), with its
dry herb weight consisting of up to 0.39 mg/100 mg of
wogonin [43]. Wogonin has been widely used in the
treatment of various inflammatory diseases owing to its
inhibition of nitric oxide (NO), prostaglandin E2 and
pro-inflammatory cytokines production, as well as its
reduction of cyclooxygenase-2 (COX-2). In vitro studies
[44-48] have shown wogonin to possess cytostatic and
cytotoxic activities against several human tumor cell
lines.
Wogonin induces apoptosis through the mediation of
Ca
2+ and/or inhibition of NF-B, shifting O2
- to H2O2
to some extent; H2O2, in turn, serves as a signaling
molecule that activates phospholipase Cg.C a
2+ efflux
from the endoplasmic reticulum is then regulated, lead-
ing to the activation of Bcl-2-associated agonist of cell
death [44]. Wogonin may also directly activate the
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2+ channel uniporter and enhance Ca
2+
uptake, resulting in Ca
2+ overload and mitochondrial
damage [44]. Furthermore, wogonin induces cell type-
dependent cell cycle inhibitions in cancer cells, such as
those observed in human cervical carcinoma HeLa cells
at the G1 phase [48] and in THP-1 cells at the G2/M
phase [46] respectively. Unlike the inhibitory effect of
baicalein and baicalin on normal human fetal lung
diploid TIG-1 cells [46], wogonin imposes minor or
almost no toxicity on normal peripheral T cells [44],
TIG-1 cells [46] and human prostate epithelial cells
[47]. This selective inhibition of wogonin is due to a
high expression of L-type voltage dependent Ca
2+ chan-
nels in cancer cells [44]. In addition, wogonin sup-
presses VEGF-stimulated migration and tube formation
in HUVEC by inhibiting VEGF receptor 2 (VEGFR2)
instead of VEGFR1 phosphorylation [49].
The synergistic effect of wogonin on chemotherapy
drugs, such as etoposide, has also been investigated.
Wogonin significantly improves etoposide-induced
apoptosis in cancer cells in a similar capacity as the
typical P-glycoprotein (P-gp) inhibitors verapamil and
cyclosporine A [50-52]. However, other P-gp substrates,
such as doxorubicin and vinblastine, do not show any
synergistic effect [52]. Similar effect was also found
when combination treatment with 5-FU in human gas-
tric MGC-803 cells and in MGC-803 transplanted nude
mice [53]. The underlying mechanisms might be due to
its pro-apoptotic effect and inhibition of NF-Bn u c l e a r
translocation activity [53].
Anti-inflammatory and anti-viral activities of wogonin
may also contribute to tumor prevention [54]. Wogonin
is a good anti-cancer candidate due to its broad toxici-
ties to various types of tumor cell lines and the low toxi-
cities to normal tissues, as well as the synergistic effects.
Silibinin
Silibinin (Figure 1D), a mixture of flavonoids derived
from Silybum marianum (Shuifeiji), is therapeutically
used for the treatment of hepatic diseases in China, Ger-
many and Japan. Silibinin has effects on many cancers,
such as prostate, colon, bladder and lung cancers
[55,56], particularly the migration, invasion and metasta-
sis of cancer cells [57]. In a transgenic adenocarcinoma
of the mouse prostate (TRAMP) mouse model, silibinin
inhibits tumor growth, progression, local invasion and
distant metastasis [56]. Silibinin induces both death
receptor-mediated and mitochondrial-mediated apopto-
sis in human breast cancer MCF-7 cells [58]. Silibinin
also reduces hepatocellular carcinoma xenograft growth
through the inhibition of cell proliferation, cell cycle
progression, as well as phosphatase and tensin homolog/
P-Akt and extracellular signal-regulated kinase (ERK)
signaling. These effects induce apoptosis and increase
histone acetylation and superoxide dismutase-1 (SOD-1)
expression on human hepatocellular carcinoma xeno-
grafts [59]. Not only does silibinin inhibit primary pro-
static tumor progress but also protects against
angiogenesis and late-stage metastasis. Therefore, silibi-
nin may have a potential for improving survival and
reducing morbidity in prostate cancer patients [60].
Silibinin exerts anti-cancer activity mainly by blocking
cell cycle progression and induces G1 cell cycle arrest in
a dose- and time-dependent manner in large cell carci-
noma H1299 and H460 cells and bronchioalveolar carci-
noma H322 cells [61]. Silibinin modulates the protein
levels of cyclin-dependent kinases (CDKs; 4, 6 and 2),
cyclins (D1, D3 and E), and CDK inhibitors (p18/
INK4C, p21/Waf1 and p27/Kip1) in a differential man-
ner in the above-mentioned cell lines [61]. Silibinin also
regulates multiple cellular proliferative pathways in can-
cer cells, including receptor tyrosine kinases (RTKs),
androgen receptors, signal transducers and activators of
transcription (STATs), NF-B [62]. Moreover, silibinin
inhibits the constitutive activation of STAT3 and causes
caspase activation and apoptotic cell death in human
prostate carcinoma DU145 cells [63].
The combined use of silibinin with 1,25-dihydroxyvita-
min D3 promotes the expression of both differentiation-
promoting and -inhibiting genes in acute myelogenous
leukemia cells and the latter can be neutralized by a
highly specific pharmacological inhibitor, suggesting the
therapeutic potential of silibinin [64].
Berberine
Berberine (Figure 1E) is an isoquinoline alkaloid isolated
from Coptidis Rhizoma (Huanglian), which is a Chinese
medicinal herb for heat dissipation and detoxification,
with its dry herb weight consisting of up to 7.1 mg/100
mg of berberine [65]. Berberine has diverse pharmacolo-
gical activities [66-70] and is especially used as an anti-
bacterial and anti-inflammatory gastrointestinal remedy
in China [71]. Berberine has anti-proliferative effects on
cancer cells has been documented [72-78]. Multiple tar-
gets of berberine have been identified, including mito-
chondria, DNA or RNA, DNA topoisomerases, estrogen
receptors, MMPs, p53 and NF-B [74,79-82]. Berberine
exerts cytotoxicity and inhibits telomerase and topoi-
somerase in cancer cells by specifically binding to oligo-
nucleotides or polymorphic nucleic acid and by
stabilizing DNA triplexes or G-quadruplexes [81,83,84];
the electrostatic interactions may be quantified in terms
of the Hill model of cooperative interactions [85].
Cell cycle regulation is a common target mechanism
in anti-cancer therapies. A low-dose (12.5-50 μM) ber-
berine treatment induces G1 phase arrest whereas doses
higher than 50 μM induce G2 phase arrest in mouse
melanoma K1735-M2 and human melanoma WM793
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B1 levels and induces cycle arrest at the G1 phase in
human lung cancer H1299 and A549 cell lines [75].
Even in anoikis-resistant human breast cancer MDA-
MB-231 and MCF-7 cells, 10 or 20 μM doses of berber-
ine is superior to 5 or 10 nM of doxorubicine respec-
tively by inducing cell cycle arrest at the G0/G1 phase
[87].
In human breast cancer MCF-7 cells, berberine
induces apoptosis through a mitochondrial dependent
pathway by increasing the Bcl-2-associated × protein
(Bax)/Bcl-2 protein ratio, activating caspases and indu-
cing poly (ADP-ribose) polymerase (PARP) cleavage
[76]. These apoptotic processes also occur in human
tongue squamous carcinoma cancer-4 and human glio-
blastoma T98G cells [73,88]. Accumulation of berberine
on mitochondrial membranes alters the binding between
adenine nucleotide translocator and bongkrekic acid,
thereby inducing depolarization and fragmentation
which may contribute to mitochondrial respiration inhi-
bition and mitochondrial dysfunction [89]. In the p53-
expressing human neuroblastoma SK-N-SH and p53-
deficient SK-N-MC cells, the role of p53 in berberine’s
anti-neoplastic function is highlighted by the cytotoxic
effects and apoptotic gene expression accompanied by
caspase-3 activation [72].
In addition to apoptotic alteration induced by berber-
ine, recent findings are about anti-cancer mechanisms
that have a higher propensity to cause autophagy. Berber-
ine induces autophagic cell death in human hepatocellu-
lar liver carcinoma cell lines (HepG2) and MHCC97-L
cells, which may be diminished by cell death inhibitor 3-
methyladenine through beclin-1 activation and mamma-
lian target of rapamycin (mTOR) signaling pathway inhi-
bition [90]. In addition, berberine also modifies LC3, an
autophagic marker, in human lung cancer A549 cells,
indicating that autophagy may play a crucial role in ber-
berine-induced cancer cell death [91].
Berberine also inhibits tumor metastasis and invasion.
For example, berberine inhibits 12-O-Tetradecanoyl-
phorbol 13-acetate (TPA)-induced cell migration and
blocks prostaglandin E (EP) receptor 4 agonist-induced
migration by reducing EP receptors 2 and 4 in A375
and Hs294 cells [92]. Even at low doses, berberine sup-
presses Rho GTPase activation and induces migration
and motility inhibition in HONE1 cells [93]. Berberine
also inhibits Rho kinase-mediated Ezrin phosphorylation
at Thr (567) in 5-8F cells, leading to a 51.1% inhibition
of tumor metastasis to the lymph nodes in vivo [94]. A
combination of As2O3 (5 μM) and berberine (10 μM)
inhibit the formation of a cell confluent layer by block-
ing PKCa and ξ, consistent with reduced levels of mye-
locytomatosis oncogene (Myc), Jun proto-oncogene,
metallothionein 1-MMP and MMP-2 [95].
Berberine enhances chemo- and radio-sensitivity,
implying its potential as an adjuvant in cancer therapy.
Combined with chemotherapy drugs such as cisplatin or
As2O3, berberine exhibits significant cytotoxicity in
HeLa and SH-SY5Y cells compared with monotherapy
[96,97]. When combined with g radiation, the apoptotic
effect is significantly enhanced in HepG2 cells [98]. Ber-
berine also alleviates chemo-resistance by down-regulat-
ing overexpressed transformed mouse 3T3 cell double
minute-2 and activating p53 in acute lymphoblastic leu-
kemia cells [99]. Berberine’s poor bioavailability makes it
less likely to be an independent anti-tumor agent
[100-102]. Berberine is nevertheless a potential natural
compound for alternative cancer therapy.
Artemisinin and its derivatives (ARTs)
Artemisinin (Figure 1F) is an active terpene of the Chi-
nese medicinal herb Artemisia annua L. (Huanghuahao)
used in China to treat malaria and fever. ARTs, such as
dihydroartemisinin (DHA) and artesunate (Figure 1G),
exhibit anti-cancer activities in vitro and in vivo
[103-106]. DHA is one of the main metabolites of ARTs
and artesunate is a semi-synthesized derivative of ARTs;
both compounds exhibit anti-cancer potentials.
The anti-cancer potential of ARTs has been demon-
strated in various cancer cells including those of leuke-
mia and other cancer cells of breast, ovary, liver, lung,
pancreas and colon [104,105]. The selective anti-cancer
potential of ARTs was related with the expression of dif-
f e r e n tm o l e c u l e ss u c ha sc - M Y C ,c d c 2 5 A ,E G F R ,g-glu-
tamycysteine synthetase (GLCLR) [105,106]. ARTs also
exert anti-cancer effects in vivo in multiple cancer types
[103,107,108]. For example, either DHA or artesunate
has anti-cancer activity against pancreatic cancer xeno-
grafts [107,109].
The anti-cancer mechanism of ARTs is likely to be
related to the cleavage of the iron- or heme-mediated
peroxide bridge, followed by the generation of reactive
oxygen species (ROS) [110-112]. According to Efferth et
al. [113], CCRF-CEM and U373 cells are sensitive to a
combined treatment of ARTs and iron (II)-glycine sul-
fate or holotransferring. Pretreatment with deferoxamine
mesylate salt (an iron chelator) visibly reduces DHA-
induced apoptosis in HL-60 leukemia cells [104]. The
anti-cancer potential of ARTs is possibly connected to
the expression of TfR. The synergism of artesunate and
iron (II)-glycine sulfate co-treatment is unsuitable for all
types of tumor cells [114]. Endoplasmic reticulum stress
is partially involved in some cases of ARTs-mediated
anti-proliferation [115,116].
ARTs induce cell cycle arrest in various cell types
[103,115,117]. For example, DHA and artesunate effec-
tively mediate G1 phase arrest in HepG2 and Hep3B
cells [103]. DHA reduces cell number in the S phase in
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also arrests the G2 phase in OVCA-420 ovarian cancer
cells [117]. Thus, ART-mediated cell cycle arrest is pos-
sibly cell type dependent. ARTs also induce apoptotic
cell death in a number of cell types, in which the mito-
chondrial-mediated apoptotic pathway plays a decisive
role [104,106]. For instance, DHA enhances Bax and
reduces Bcl-2 expression in cancer cells [103,107].
DHA-induced apoptosis is abrogated by the loss of Bak
and is largely reduced in cells with siRNA-mediated
downregulation of Bak or NOXA [118]. However, DHA
activates caspase-8, which is related to the death recep-
tor-mediated apoptotic pathway in HL-60 cells [104].
DHA enhances Fas expression and activates caspase-8
in ovarian cancer cells [119]. DHA also enhances death
receptor 5 and activates both mitochondrial- and death
receptor-mediated apoptotic pathways in prostate cancer
cells [120]. ARTs-induced apoptosis in cancer cells may
involve p38 MAPK rather than p53 [103,104].
ARTs inhibit angiogenesis which is a vital process in
metastasis [121-124]. DHA inhibits chorioallantoic
membrane angiogenesis at low concentrations and
decreases the levels of two major VEGF receptors on
HUVEC [122]. Conditioned media from K562 cells pre-
treated with DHA inhibits VEGF expression and secre-
tion in chronic myeloid leukemia K562 cells, leading to
angiogenetic activity decrease [121,124]. Artemisinin
inhibits cell migration and concomitantly decreases the
expression of MMP2 and the avb3 integrins in human
melanoma cells [125]. ARTs also regulate the levels of
u-PA, MMP2, MMP7 and MMP9 all of which are
related to metastasis [126].
ARTs exert synergistic effects with other compounds.
Combination of DHA and caboplatin significantly
reduces the development of ovarian cancer as compared
with DHA only [119]. Combined use of DHA or artesu-
nate with gencitabine inhibits the growth of HepG2 and
Hep3B transplanted tumors [103]. Supra-additive inhibi-
tion of cell growth in some glioblastoma multiforme
cells is observable when artesunate is in combined use
with EGFR inhibitor OSI-774 [127]. DHA not only up-
regulates death receptor 5 expression but also coop-
erates with TNF-related apoptosis-inducing ligand
(TRAIL) to induce apoptosis in human prostate cancer
cells [120]. Therefore, either used alone or in combina-
tion with other compounds, ARTs are promising com-
pounds for chemotherapy.
b-elemene
Elemene (Figure 1H) is a sesquiterpene mixture isolated
from more than 50 Chinese herbs and plants, such as
Curcuma wenyujin Y. H. Chen et C. Ling (Wenyujin)
[128]. Elemene is mainly composed of b-a n dδ-a n dg-
elemene, with b-elemene accounting for 60%-72% of all
three isoforms. b-elemene exerts anti-cancer potential in
brain, laryngeal, lung, breast, prostate, cervical, colon
and ovarian carcinomas [128-130]. Elemene shows
synergistic effects in combination with other chemother-
apeutic drugs [131], leading to the blockade of cell cycle
progression by modulating the G2 cell cycle checkpoint
and inducing G2/M arrest in human non-small cell lung
cancer (NSCLC) and ovarian carcinoma cells while
inducing G0/G1 phase arrest in glioblastoma cell lines
through phosphorylation of p38 MAPK [129,130,132].
In NSCLC cells, b-elemene induces cell arrest at the
G 2 / Mp h a s eb yi n c r e a s i n gp h o s p h o - C d c 2( T y r 1 5 )a n d
p27/Kip1, and by decreasing phospho-Cdc2 (Thr161)
and cyclin B1. Moreover, elemene reduces the expres-
sion of Cdc25C, activates Cdc2 and increases Chk2
[129]. b-elemene combined with cisplatin also mediate
G2/M cell cycle arrest in chemo-resistant ovarian carci-
noma cells through down-regulation of cyclin B1 and
Cdc2 by elevating the levels of phosphorylation of Cdc2,
Cdc25C, p53, p21/Waf1, p27/Kip1 and GADD45 [130].
b-elemene also induces mitochondrial-mediated apopto-
sis in prostate cancer and NSCLC cells [128,129]. Com-
bining b-elemene with cisplatin, docetaxel and taxanes
significantly increases its inhibitory effect in androgen-
independent prostate carcinoma DU145 and PC-3 cells,
as well as in NSCLC H460 and A549 cells [131]. b-ele-
mene enhances cellular uptake of taxanes due to the
alteration of cell membrane permeability may partly
account for its synergistic effects with taxanes [131]. Ele-
mene inhibits the growth of human epidermoid and
thyroid cancer cells in vivo [133], and passes through
the blood-brain barrier [134], suggesting its potential for
treating cerebral malignancy.
b-elemene has been approved by China’s State Food
and Drug Administration as a second class innovative
drug and is prescribed as an adjuvant drug for some
tumor therapies in China.
Oridonin
Oridonin (Figure 1I) is a diterpenoid isolated from Rab-
dosia rubescens (Hemsl.) Hara (Donglingcao), with its
dry raw herb consisting of up to 0.35% of oridonin
[135]. Rabdosia rubescens (Hemsl.) Hara has long been
used to treat sore throat, tonsillitis, and esophageal can-
cer by native residents of Henan Province. Oridonin was
included in the Chinese Pharmacopoeia in 1977. Main
chemical constituents of Rabdosia rubescens (Hemsl.)
Hara are ent-Kaurene diterpenoids, which have multiple
biological activities, such as anti-inflammatory, anti-bac-
terial and anti-tumor effects.
Oridonin significantly inhibits tumor cell proliferation,
induces cell cycle arrest and promotes cell death. In
anti-proliferation tests, different cell lines exhibited simi-
lar sensitivity to oridonin with an IC50 of about 40-80
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induces G2/M cell cycle arrest by up-regulation of heat
shock 70 kDa protein 1, serine-threonine kinase recep-
tor-associated protein, translationally controlled tumor
protein, stress-induced phosphoprotein 1, trifunctional
purine biosynthetic protein adenosine-3 and inorganic
pyrophosphatase as well as down-regulation of poly(rC)-
binding protein 1 [142] in a p53-independent and p21/
Waf1-dependent manner [143]. Induction of apoptosis
contributes to oridonin-induced cell death, mainly
through mitochondrial-mediated pathways. The up-reg-
ulation of Fas, Fas ligand (FasL) and Fas (TNFRSF6)-
associated via death domain (FADD) expression, as well
as the down-regulation of pro-caspase-8 expression sug-
gests that the activation of the Fas/FasL pathway may
also be partially involved in oridonin-induced apoptosis
[144]. Possible downstream responses include the induc-
tion of loss of mitochondrial transmembrane potential
[145], the activation of several caspases [136,146], the
down-regulation of Bcl-2, the up-regulation of Bax and
Bid [136,147] as well as the promotion of cytochrome c
release [147] and PARP cleavage [148]. However, the
regulation of Bcl-xL and participation of caspase-3/9
remain controversial [136,143,146,148-150]. Oridonin-
induced intracellular ROS formation may be an initiator
of this process [143,151]. Other proteins may also be
involved in oridonin-induced cell cycle arrest and apop-
tosis; these proteins include ERK [144,152], p38MAPK
[149], insulin-like growth factor 1 receptor [153], EGFR
[154], NF-B [155], as well as p16, p21/Waf1, p27/Kip1
and c-MYC [156]. Oridonin induce cell death by affect-
ing the balance of apoptosis and necrosis. In A375-S2
cells, low concentrations (34.3 μM) of oridonin induce
p53 and ERK-dependent apoptosis whereas high con-
centrations (137.4 μM) induce necrosis [146]. In L929
cells, oridonin induces a caspase-independent and mito-
chondria- or MAPK-dependent cell death through both
apoptosis and necrosis [139,149]. Similar results are also
observed in A431 cells [154]. Oridonin also induces
simultaneous autophagy and apoptosis in MCF-7 [157]
and HeLa cells [138]. This autophagy may be attributed
to the inactivation of Ras, changes in mitochondrial
membrane potential [158], activation of PKC, Raf-1 or
c-jun N-terminal kinase (JNK) signaling [141] and even
NF-B signaling pathways [159]. Inhibition of autophagy
is attributed to apoptotic up-regulation because orido-
nin-induced apoptosis augmentation is accompanied by
reduced autophagy [138] whereas oridonin-induced
autophagy inhibits ROS-mediated apoptosis by activat-
ing the p38 MAPK-NF-B survival pathways in L929
cells [160]. Oridonin inhibits DNA, RNA, and protein
syntheses [161], decrease telomerase, as well as down-
regulate human telomerase reverse transcriptase mRNA
expression [162]. The in vivo anti-tumor activities of
oridonin have been demonstrated in different tumors
such as Ehrlich ascites carcinoma, sarcoma-180 solid
tumors and in leukemic mice models [163,164].
Triptolide
Triptolide (Figure 1J) is a diterpenoid triepoxide and the
principal active ingredient of Tripterygium wilfordii
Hook. f.( Leigongteng) used in Chinese medicine to treat
inflammation and autoimmune diseases [165]. Triptolide
exhibits potent anti-inflammation, immunomodulation
and anti-tumor activities [166-170]. Triptolide exerts
multiple effects on apoptosis, angiogenesis, metastasis
and drug-resistance [166-170].
Triptolide is active in pro-apoptosis in diverse tumor
cell types including ovarian cancer [166], myeloma
[167], myeloid leukemia [168], thyroid carcinoma [169]
and pancreatic tumor cells [170]. Many in vitro and in
vivo studies have tried to elucidate the potential
mechanism of triptolide; however, conclusions have
been inconsistent. Triptolide seems to induce apoptosis
via different pathways in various cell lines. For example,
triptolide induces apoptosis by the overexpression of
cytomembrane death receptor in a caspase-8-dependent
manner in pancreatic tumor [170] and cholangiocarci-
noma cells [171]. Triptolide also promotes apoptosis in
leukemic and hepatocarcinoma cells by the mitochon-
drial-mediated pathway [172,173].
Triptolide is a potent inhibitor of tumor angiogenesis
in a zebrafish embryo model and demonstrates potent
activities against vessel formation by nearly 50% at 1.2
μM [165]. In a xenograft model, triptolide (0.75 mg/kg/
day) blocks tumor angiogenesis and progression in a
murine tumorigenesis assay possibly correlated with the
down-regulation of proangiogenic Tie2 and VEGFR-2
expression [174]. In vitro studies have shown that tripto-
lide inhibits the proliferation of HUVEC. A chick
embryo chorioallantoic membrane test shows that trip-
tolide inhibits angiogenesis as well. Triptolide impairs
VEGF expression in thyroid carcinoma TA-K cells and
down-regulates NF-B pathway activity; the target genes
of triptolide are associated with endothelial cell mobili-
zation in HUVEC [165]. The down-regulation of NF-B
signaling [175], in combination with the inhibition of
VEGF expression [176], may be the anti-angiogenesis
action of triptolide.
Furthermore, triptolide inhibits tumor metastasis,
reducing basal and stimulated colon cancer cell migra-
tion through collagen by 65% to 80% and decreasing the
expression of VEGF and COX-2 [174]. Triptolide inhi-
bits the expression of multiple cytokine receptors poten-
tially involved in cell migration and cancer metastasis,
including the thrombin receptor, CXCR4, TNF receptors
and TGF-b receptors [174]. Triptolide also inhibits
interferon-g-induced programmed death-1-ligand 1
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mechanism of tumor immune evasion in human breast
cancer cells [177]. Triptolide inhibits the experimental
metastasis of melanoma cells to the lungs and spleens of
mice [178]. Moreover, triptolide inhibits the migration
of lymphoma cells via lymph nodes, a result which may
be related to its anti-proliferative effects and blockage of
the SDF-1/CXCR4 axis [179].
Triptolide enhances the anti-neoplastic activity of che-
motherapy [180,181]. The combination index-isobolo-
gram indicates that the effect of triptolide on 5-FU is
synergistic on colon carcinoma [180]. In a tumor xeno-
graft model, the combined effects of triptolide (0.25 mg/
kg/day) and 5-FU (12 mg/kg/day) on the growth of
colon carcinoma are superior to those of individual
agents [180]. Triptolide is synergistic with other anti-
cancer agents or therapies including hydroxycamptothe-
cin [181], idarubicin, AraC [182], TRAIL [183] and
ionizing radiation [184]. These results indicate the ther-
apeutic potential of triptolide in treating cancer.
Ursolic acid (UA)
UA (Figure 1K) is a ubiquitous pentacyclic triterpenoid
compound from many plants such as Ligustrum lucidum
Ait. (Nuzhen). UA exerts proliferation inhibition in human
ovarian cancer CAOV3 cells and doxorubicin-resistant
human hepatoma R-HepG2 cells [185,186]. UA disrupts
cell cycle progression and induces necrosis in a clonal
MMTV-Wnt-1 mammary tumor cell line [187]. Eight
novel UA derivatives with substitutions at positions C-3,
C-11, and C-28 of UA show cytotoxicity to some degree
in HeLa, SKOV3 and BGC-823 in vitro; only one deriva-
tive exhibits more potent cytotoxicity than UA [188].
UA induces apoptosis via both extrinsic and intrinsic
signaling pathways in cancer cells [189]. In PC-3 cells,
UA inhibits proliferation by activating caspase-9 and
JNK as well as FasL activation and Akt inhibition [190].
A significant proliferation inhibition and invasion sup-
pression in both a dose- and time-dependent manner is
observed in highly metastatic breast cancer MDA-MB-
231 cells; this inhibition is related to the down-regula-
tion of MMP2 and u-PA expression [191]. Moreover,
UA reduces IL-1b-o rT N F - a-induced rat C6 glioma
cell invasion and inhibits the interaction of ZIP/p62 and
PKC-ζ [192]. Nontoxic UA concentrations inhibit vessel
growth in rat aortic ring and down-regulate matrix
MMPs such as MMP2 and MMP9 [193]. In other can-
cer cell lines, such as Hep3B, Huh7 and HA22T cells,
UA exerts a potential anti-angiogenic effect by decreas-
ing HIF-1a, VEGF and IL-8 gene expression [194].
Shikonin
Shikonin (Figure 1L) is a natural anthraquinone derivative
isolated from the roots of Lithospermum erythrorhizon
(Zicao) and exerts anti-tumor effects mainly by inhibiting
cell growth and inducing apoptosis. The underlying mole-
cular mechanisms vary with cell types and treatment
methods. Shikonin induces apoptosis in a classic caspase-
dependent pathway in cervical, bladder and melanoma
cancer cells [195-198]. Shikonin induces necroptosis
regardless of the drug concentration in caspase-3-negative
MCF-7 cells [199]. Different concentrations of shikonin
induce either apoptosis or necroptosis, and necroptosis
converts to apoptosis in the presence of Nec-1 in HL-60
and K562 cells [200]. The growth inhibition and apoptosis
induced by shikonin in some cancer cells may be attribu-
ted to the inactivation of NF-B activity or increasing
Annexin V signal and CD95 (Fas/APO) expression
[201,202]. Shikonin also induces apoptosis via ROS pro-
duction in osteosarcoma and Bcr/Abl-positive CML cells
[203,204].
Several different mechanisms contribute to the anti-
cancer activities of shikonin. For example, shikonin sup-
presses proteasomal activities thereby inhibiting tumor
growth in both H22 allografts and PC-3 xenografts
[205]. Shikonin also inhibits topoisomerase II [206] and
down-regulates ER2 and activates NFE2-related factor 2
as an anti-estrogen agent in human breast cancer
[207,208]. Shikonin modulates an estrogen enzyme by
down-regulating the expression of steroid sulfatase
which is important for estrogen biosynthesis [205]. Shi-
konin inhibits tumor invasion via the NF-Bs i g n a l i n g
pathway in human high-metastatic adenoid cystic carci-
noma cells [209]. Therefore, shikonin may directly or
indirectly inhibit or modulate disease-related cellular
targets in cancer.
Emodin
Emodin (Figure 1M) is a natural anthraquinone deriva-
tive isolated from Rheum palmatum L. (Zhangyeda-
huang), with its dry raw herb consisting of up to 0.20
mg/100 mg of emodin [210]. Emodin exerts anti-tumor
activity against various human cancers [211]. Emodin
induces cell cycle arrest and apoptosis in cancer cells
[212-214] and the oxidative injury acts upstream of anti-
proliferation. Emodin inhibits IL-6-induced Janus-acti-
vated kinase 2/STAT3 pathways and induces apoptosis
in myeloma cells via the down-regulation of Mcl-1
[213]. Emodin down-regulates androgen receptors and
inhibits prostate cancer cell growth [215]. Moreover,
emodin stabilizes topoisomerase II-DNA cleavage com-
plexes, thereby inducing DNA double-strand breaks
[216]. The suppression of excision repair cross comple-
mentation 1 (ERCC1) and Rad51 expression through
ERK1/2 inactivation is vital in emodin-induced cytotoxi-
city in human NSCLC cells [217].
Emodin inhibits basic fibroblast growth factor (bFGF)-
induced proliferation and m i g r a t i o ni nH U V E Ca n d
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tumor cell migration through suppression of the phos-
phatidylinositol 3-kinase-Cdc42/Rac1 pathway [219].
The disruption of the membrane lipid raft-associated
integrin signaling pathway by emodin may inhibit cell
adhesion and spreading [220].
Emodin sensitizes chemotherapy associated with ROS
production [221,222]. In combined use with cisplatin,
emodin elevates ROS generation and enhances chemo-
sensitivity in DU-145 cells, accompanied by the down-
regulation of MDR1 expression and suppression of HIF-
1a transactivation [223]. Emodin enhances the sensitiv-
ity of gallbladder cancer SGC996 cells to platinum drugs
via glutathione depletion and multidrug resistance-
related protein 1 down-regulation [224]. The mechan-
isms of the synergistic effects of emodin with cisplatin
or gencitabin may be attributed to the emodin-induced
down-regulation of ERCC1 and Rad51 expression,
respectively [225,226]. These results suggest that emodin
may be used as an adjuvant to enhance the anti-cancer
effects of chemotherapeutic agents.
Ginsenoside Rg3
Extracted from Panax ginseng C.A. Mey. (Renshen)a n d
Panax quinquefolius L., Araliaceae (Xiyangshen), ginse-
noside Rg3 (Figure 1N) is a biologically active compo-
nent with both in vitro and in vivo anti-cancer activities
[227,228]. The anti-proliferative mechanism of ginseno-
side Rg3 is associated with the inactivation of NF-B
[229,230], modulation of MAPKs [231] and the down-
regulation of Wnt/b-catenin signaling [232]. Ginsenoside
Rg3 affects the ephrin receptor pathway in HCT-116
human colorectal cancer cells [233]. The anti-prolifera-
tive mechanism of ginsenoside Rg3 is also associated
with the molecules of mitotic inhibition, DNA replica-
tion, repair, and growth factor signaling [234].
Ginsenoside Rg3 inhibits the proliferation of HUVEC
and suppresses the capillary tube formation of HUVEC
on a matrigel at nanomole scales in the presence or
absence of VEGF. Ginsenoside Rg3 attenuates VEGF-
induced chemo-invasion of HUVEC and ex vivo micro-
vascular sprouting in rat aortic ring. bFGF-induced
angiogenesis may be abolished by ginsenoside Rg3
[227]. In lung metastasis models of ovarian cancer,
ginsenoside Rg3 decreases the number of tumor colo-
nies in the lung and vessels oriented toward the tumor
mass [235]. This effect may be partially due to the
inhibition of angiogenesis and the decrease in MMP9
expression [235].
Ginsenoside Rg3 increases the efficacy of cancer che-
motherapy. Combined treatments with ginsenoside Rg3
enhance the susceptibility of colon cancer cells to doce-
taxel, paclitaxel, cisplatin and doxorubicin; the mechan-
ism of such an enhancement is related to the inhibition
of the constitutively activated NF-B [229]. A similar
phenomenon has been observed in prostate cancer cells,
in which the combination of ginsenoside Rg3 and doce-
taxel more effectively induces apoptosis and G1 cell
cycle arrest, accompanied by the inhibition of NF-B
activity [230]. Low-dose administration of cyclophospha-
mide (CTX) with ginsenoside Rg3 increases the efficacy
of targeting the tumor microvasculature and the two-
drug combination treatment results demonstrate the
longest patient survival rates [236]. Ginsenoside Rg3
combined with gemcitabine not only enhances the effi-
cacy of tumor growth suppression and survival prolon-
gation, but also decreases VEGF expression and
microvessel density in tumors [228].
Conclusion
Natural products such as GA, curcumin, b-elemene et
al. derived from Chinese medicinal herbs are potential
candidates for anti-cancer therapeutic drugs.
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